p27(kip1) functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes

Nature Medicine

Volumn 6, Issue 3, 2000, Pages 290-297

  Boussiotis, Vassiliki A ^a   Freeman, Gordon J ^a   Taylor, Patricia A ^b   Berezovskaya, Alla ^a   Grass, Isabelle ^a   Blazar, Bruce R ^b   Nadler, Lee M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; HLA DR7 ANTIGEN; INTERLEUKIN 2; PROTEIN P27; TRANSCRIPTION FACTOR AP 1; CCND2 PROTEIN, HUMAN; CCND2 PROTEIN, MOUSE; CDK4 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CLONAL ANERGY; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CLONE; CELL CYCLE G1 PHASE; CELL STRAIN COS1; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CLONAL ANERGY; CLONE CELLS; COS CELLS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; MICE; MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0033621780     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/73144     Document Type: Article

References (45)

1. Schwartz, R.H. T-cell clonal anergy. Curr. Opin. Immunol. 9, 351-357 (1997).
2. Larsen, C.P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434-438 (1996).
3. Kirk, A.D. et al. CTLA4-lg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. 94, 8789-8794 (1997).
4. Blazar, B.R., Taylor, P.A., Linsley, P.S. & Vallera, P.A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-lg reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825 (1994).
5. + T-cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host lethality capacity but retain normal antigen responses. J. Clin. Invest. 102, 473-482 (1998).
6. Guinan, E.C. et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714 (1999).
7. Cho, E.A., Riley, M.P., Sillman, A.L. & Quill, H. Altered protein tyrosine phosphorylation in anergic Th1 cells. J. Immunol. 151, 20-28 (1993).
8. Madrenas, J. et al. ζ phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267, 515-518 (1994).
9. Boussiotis, V.A. et al. Differential association of protein tyrosine kinases with T-cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J. Exp. Med. 184, 365-376 (1996).
10. + T-cells. Science 271, 1276-1278 (1996).
11. Kang, S.M. et al. Transactivation by AP-1 is a molecular target of T-cell clonal anergy. Science 257, 1134-1138 (1992).
12. Mondino, A. et al. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB and JunB in anergic T helper 1 cells. J. Immunol. 157, 2048-2057 (1996).
13. fyn. J. Immunol. 149, 2887-2893 (1992).
14. Gajewski, T.F., Qian, D., Fields, P. & Fitch, F.W. Anergic T-lymphocyte clones have altered inositol phosphate, calcium and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA 91, 38-42 (1994).
15. Cajewski, T.F., Fields, P. & Fitch, F.W. Induction of the increased fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur. J. Immunol. 25, 1836-1842 (1995).
16. Sloan-Lancaster, J., Steinberg, T.H. & Allen, P.M. Selective activation of the calcium signaling pathway by altered peptide ligands. J. Exp. Med. 184, 1525-1530 (1996).
17. Boussiotis, V.A., Freeman, G.J., Berezovskaya, A., Barber, D.L. & Nadler, L.M. Maintenance of human T-cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 278, 124-128 (1997).
18. Beverly, B., Kang, S.M., Lenardo, M.J. & Schwartz, R.H. Reversal of in vitro T-cell clonal anergy by IL-2 stimulation. Int. Immunol. 4, 661-671 (1992).
19. Gilbert, K.M. & Weigle, W.O. Th1 cell anergy and blockade in G1 a phase of the cell cycle. J. Immunol. 151, 1245-1254 (1993).
20. DeCaprio, J.A., Furukawa, T., Ajchenbaum, F., Griffin, J.D. & Livingston, D.M. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl.Acad Sci. USA 89, 1795-1798 (1992).
21. Sherr, C.J. & Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
22. kpl. EMBO J. 17, 5334-5344 (1997).
23. Ajchenbaum, F., Ando, K., DeCaprio, J.A. & Griffin, J.D. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J. Biol. Chem. 268, 4113-4119 (1993).
24. kpl expression following the polyclonal activation of murine Go T-cells. J. Immunol. 158, 5642-5648 (1997).
25. Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 366, 704-704 (1993).
26. Chan F.K., Zhang, J., Cheng, L., Shapiro, D.N. & Winoto, A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to P16ink4. Mol. Cell. Biol. 15, 2682-2688 (1995).
27. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
28. kip1 mRNA and protein in murine B cells. J. Immunol. 160, 770-777 (1998).
29. kip1) of cyclin-dependent kinase 4 activation. Cell 79, 487-496 (1994).
30. Elliot, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herper-virus structural protein. Cell 88, 223-233 (1997).
31. Waga, S., Hannon, G.J., Beach, D. & Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578 (1994).
32. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570-573 (1994).
33. kip1 is instigated by Jab1. Nature 398, 160-165 (1999).
34. Claret, F.X., Hibi, M., Dhut, S., Toda, T. & Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383, 453-457 (1996).
35. Grewal, I.J. & Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
36. Tamir A., Granot, Y. & Isakov, N. Inhibition of T lymphocyte activation by cAMP is associated with downregulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J. Immunol. 157, 1514-1522 (1996).
37. Li, L., Yee, C. & Beavo, J.A. CD3-and CD28-dependent induction of PDE7 required for T-cell activation. Science 283, 848-851 (1999).
38. de Rooij, J. et al. Epac is a Rap1 guanidine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474-477 (1998).
39. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. A ras-related gene with transformation suppressor activity. Cell 56, 77-84 (1989).
40. kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15, 629-237 (1997).
41. ras. J. Exp. Med. 180, 1067-1076 (1994).
42. Powell, J.D., Lerner, C.G. & Schwartz, R.H. Inhibition of cell cycle progression by rapamycin induces T-cell clonal anergy even in the presence of costimulation. J. Immunol. 162, 2775-2784 (1999).
43. Li, Y., Zheng, X.X., Li, X.C., Zand, M.S. & Strom, T.B. Combined costimulation blockade plus rapamycin but not cyclosporin produces permanent engraftment. Transplantation 66, 1387-1388 (1998).
44. Granger, D. et al. Prolonged survival without posttransplant immunosuppression in a large animal model. Surgery 116, 236-241 (1994).
45. Matsushime, H. et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066-2076 (1994).